Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

摘要: Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with wide variety of clinical manifestations. Advances in treatment over the last decades, such as use corticosteroids conventional immunosuppressive drugs, have improved life expectancy SLE sufferers. Unfortunately, many cases effective management still related to severe drug-induced toxicity contributes function deterioration infective complications, particularly among patients refractory and/or nephritis. Consequently, there unmet need for drugs better efficacy safety profile. A range different biologic agents been proposed subjected trials, dedicated this subset whose inadequately controlled by regimes. most these trials given unsatisfactory results, belimumab being only targeted therapy approved so far. Despite pitfalls, several novel targeting B cells, T or cytokines are constantly evaluated trials. It seems they enhance therapeutic when combined standard therapies. These efforts raise hope be available near future. This article reviews current biological therapies tested SLE.